Summary of HR 2592: Aviation Medication Transparency Act of 2025

Purpose and Intent

The Aviation Medication Transparency Act of 2025 (HR 2592) aims to enhance the safety and transparency of medication use among aviation personnel, including pilots and flight attendants. The bill seeks to ensure that all medications that could potentially affect an individual's ability to perform their duties are disclosed and regulated effectively.

Key Provisions

The bill includes several significant provisions designed to improve medication transparency in the aviation industry:

• Disclosure Requirements: Aviation personnel will be required to disclose any medications they are taking that may impair their ability to operate an aircraft safely. This includes both prescription and over-the-counter medications.

• Regulatory Framework: The bill mandates the Federal Aviation Administration (FAA) to establish guidelines for the safe use of medications by aviation personnel. This includes creating a list of medications that are prohibited or restricted for use while on duty.

• Training and Education: The FAA will be tasked with developing training programs for aviation personnel regarding the effects of various medications on performance and safety. This aims to foster a culture of safety and awareness within the industry.

• Reporting Mechanism: The bill proposes the establishment of a reporting mechanism for incidents related to medication use that could impact aviation safety. This will help in gathering data and improving regulations over time.

Affected Parties

The primary stakeholders affected by this legislation include:

• Aviation Personnel: Pilots, flight attendants, and other aviation staff who are required to take medications will be directly impacted by the new disclosure and training requirements.

• Airlines and Aviation Companies: Airlines will need to comply with the new regulations, which may involve updating their policies and training programs to align with the bill's provisions.

• Regulatory Bodies: The FAA will have an expanded role in overseeing medication use among aviation personnel, requiring additional resources and potential adjustments to existing regulatory frameworks.

Procedural Aspects

• Introduced Date: The bill was introduced in the House on April 02, 2025.

• Legislative Actions: Following its introduction, HR 2592 was referred to the House Committee on Transportation and Infrastructure and subsequently to the Subcommittee on Aviation on the same day.

• Sponsorship: The bill is primarily sponsored by Sean Casten, with Pete Stauber serving as a cosponsor, indicating bipartisan support for the initiative.

Conclusion

The Aviation Medication Transparency Act of 2025 represents a proactive approach to ensuring safety in the aviation industry by addressing the potential risks associated with medication use among aviation personnel. By establishing clear guidelines and promoting education, the bill aims to enhance the overall safety of air travel for both crew members and passengers.